基于微小残留病的移植物抗宿主病与移植物抗白血病效应在费城染色体阳性急性淋巴细胞白血病中的影响
以时间依赖协变量分析显示,轻度急性GVHD和慢性GVHD与总死亡率无显著关联,而重度急性GVHD因高非复发死亡率导致总生存更差;按MRD状态分层后急慢性GVHD均未显著改善总生存。因此不推荐为追求GVL效应而降低GVHD预防强度。
要点
- 按MRD分层后GVHD未显著改善总生存。
核心结论
- 在Ph阳性ALL首次完全缓解期移植患者中,轻度急性GVHD和慢性GVHD与总死亡率无显著关联,重度急性GVHD导致总生存更差。
- 按MRD状态分层后,急性和慢性GVHD均未与更好的总生存显著相关,故不推荐通过降低GVHD预防强度来追求GVL效应。
研究设计与样本
- 回顾性分析1022例首次完全缓解期接受首次异基因造血干细胞移植的Ph阳性ALL患者。
- 将GVHD作为时间依赖协变量,调整其他可能变量后分析对移植结局的影响。
主要发现
- 按MRD状态分层后,急性和慢性GVHD均未与更好的总生存显著相关。
临床怎么用
- 对于Ph阳性ALL首次完全缓解期移植患者,不应为追求GVL效应而降低GVHD预防强度。
- 需重视重度急性GVHD的防治以降低非复发死亡率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The impacts of graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) effect might differ depending on minimal residual disease (MRD). Therefore, we examined 1,022 recipients who underwent their first allogeneic hematopoietic stem cell transplantation (HSCT) for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL) in first complete remission. MRD status at HSCT was negative in 791 (77·4%) and positive in 231 (22·6%). The impact of GVHD as a time-dependent covariate on transplant outcomes were analyzed while adjusting for other possible variables. Mild acute GVHD [hazard ratio (HR), 0·90; 95% confidence interval (CI), 0·70-1·16; P = 0·901] and chronic GVHD (HR, 0·82, 95% CI, 0·58-1·14; P = 0·238) were not significantly associated with overall mortality, whereas severe acute GVHD (HR, 2·26, 95% CI, 1·64-3·11; P < 0·001) resulted in inferior overall survival due to high non-relapse mortality. Moreover, even in the subgroup analyses stratified according to MRD status, acute and chronic GVHD were not significantly associated with better overall survival. Therefore, less intensive GVHD prophylaxis to achieve a GVL effect is not recommended for Ph-positive ALL.
引用
- Akahoshi Y, Igarashi A, Fukuda T, et al. Impact of graft-versus-host disease and graft-versus-leukemia effect based on minimal residual disease in Philadelphia chromosome-positive acute lymphoblastic leukemia. Br J Haematol. 2020. PMID: 32119132. doi:10.1111/bjh.16540
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。